EGFR and non-small cell lung carcinoma: Secondly, hsa-miR-125b could help reduce the number of metastases in patients with NSCLC along with hsa-miR-133b, which correlates with tumour stage, degree of invasion, and EGFR expression, which may play an important role not only in prognostic but also in the treatment with drugs directed towards the EGFR. Finally, it has been described that the hsa-miR-128 correlates with high survival after treatment with gefitinib [18].